Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs

Rhea-AI Filing Summary

Graff Jeremy R. reported acquisition or exercise transactions in this Form 4 filing.

Allarity Therapeutics, Inc. reported that officer Jeremy R. Graff received a grant of 133,333 shares of common stock in the form of restricted stock units on January 28, 2026. The award was granted at a stated price of $0.00 per share as equity compensation.

The RSUs were issued under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan and will vest in three equal installments on the first, second, and third anniversaries of the grant date, as long as Graff maintains a continued relationship with the company. Following this grant, he directly holds 381,644 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Graff Jeremy R.

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	133,333	$0.00	--

Holdings After Transaction: Common Stock — 381,644 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 133,333 shares Grant price: $0.00 per share Post-grant holdings: 381,644 shares +2 more

5 metrics

RSU grant size 133,333 shares Restricted stock units granted on January 28, 2026

Grant price $0.00 per share Stated transaction price for RSU grant

Post-grant holdings 381,644 shares Total common stock directly held after the grant

Vesting schedule 1/3 annually over 3 years RSUs vest on first, second, and third anniversaries of grant

Transaction code A Grant, award, or other acquisition of non-derivative common stock

Key Terms

restricted stock units, Amended and Restated 2021 Equity Incentive Plan, vesting, grant, award, or other acquisition

4 terms

restricted stock units financial

"The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2021 Equity Incentive Plan financial

"granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan"

vesting financial

"will vest in equal one-third installments on the first, second, and third anniversary of the grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Graff Jeremy R.

(Last) (First) (Middle)

C/O ALLARITY THERAPEUTICS, INC.

123 E TARPON AVE

(Street)

TARPON SPRINGS FLORIDA 34689

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allarity Therapeutics, Inc. [ ALLR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/16/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		133,333(1)	A	$0	381,644	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

Remarks:

President and Chief Development Officer

	/s/ Jeremy R. Graff	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Allarity Therapeutics (ALLR) report for Jeremy R. Graff?

Allarity Therapeutics reported that officer Jeremy R. Graff received 133,333 restricted stock units of common stock on January 28, 2026. This was a share grant under the company’s Amended and Restated 2021 Equity Incentive Plan, not an open-market purchase or sale.

How many Allarity Therapeutics (ALLR) shares does Jeremy R. Graff hold after this Form 4/A?

After the January 28, 2026 grant, Jeremy R. Graff directly holds 381,644 shares of Allarity Therapeutics common stock. This total includes the newly awarded 133,333 restricted stock units, which will vest over three years, subject to his continued relationship with the company.

What are the vesting terms of Jeremy R. Graff’s Allarity Therapeutics (ALLR) RSU grant?

The 133,333 restricted stock units granted to Jeremy R. Graff vest in three equal one-third installments on the first, second, and third anniversaries of the January 28, 2026 grant date. Vesting requires his continued relationship with Allarity Therapeutics through each applicable vesting date.

Was cash paid for Jeremy R. Graff’s Allarity Therapeutics (ALLR) RSU award?

No cash was paid for this award. The Form 4/A lists a transaction price of $0.00 per share for the 133,333 restricted stock units, reflecting an equity compensation grant provided under Allarity Therapeutics, Inc.’s Amended and Restated 2021 Equity Incentive Plan.

Is the Allarity Therapeutics (ALLR) Form 4/A transaction a market buy or sell?

The transaction is not a market buy or sell. The Form 4/A shows code “A,” indicating a grant or award acquisition of 133,333 restricted stock units to Jeremy R. Graff as part of his compensation, rather than an open-market trading transaction.